SCHEDULE 13G 0001633313 XXXXXXXX LIVE Ordinary shares, nominal value 0.002 GBP per share 09/30/2025 0001847903 Centessa Pharmaceuticals plc 152309100 3RD FLOOR 1 ASHLEY ROAD ALTRINCHAM, CHESHIRE X0 WA14 2DT Rule 13d-1(b) Avoro Capital Advisors LLC b DE 10808080.00 0.00 10808080.00 0.00 10808080.00 N 8.06 IA OO Represented by 10,808,080 ADSs (as defined in Item 2(a)). Behzad Aghazadeh b X1 10808080.00 0.00 10808080.00 0.00 10808080.00 N 8.06 HC IN Represented by 10,808,080 ADSs. Centessa Pharmaceuticals plc 3rd Floor, 1 Ashley Road, Altrincham, Cheshire, X0, WA14 2DT This statement is filed by: (i) Avoro Capital Advisors LLC, a Delaware limited liability company ("Avoro"), which provides investment advisory and management services and has acquired American Depositary Shares, each representing one ordinary share, nominal value (pound) 0.002 per share ("Ordinary Shares") of Centessa Pharmaceuticals PLC, a limited liability company incorporated under the laws of England and Wales (the "Company") underlying the ADSs (as defined below), solely for investment purposes on behalf of Avoro Life Sciences Fund LLC, a Delaware limited liability company, and (ii) Behzad Aghazadeh ("Dr. Aghazadeh," and together with Avoro, the "Reporting Persons"), who serves as the portfolio manager and controlling person of Avoro. The filing of this statement should not be construed as an admission that any Reporting Person is, for purposes of Section 13 of the Act, the beneficial owner of the securities reported herein. There is no CUSIP number assigned to the Ordinary Shares. The CUSIP number 152309100 has been assigned to the American Depositary Shares ("ADSs") of the Company, which are quoted on the Nasdaq Global Select Market under the symbol "CNTA." Each ADS represents one Ordinary Share. The address of the business office of each of the Reporting Persons is 110 Greene Street, Suite 800, New York, NY 10012. Avoro is a Delaware limited liability company. Dr. Aghazadeh is a United States citizen. N IA HC The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 134,073,436 Ordinary Shares outstanding as of August 1, 2025, as reported in the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2025, filed with the Securities and Exchange Commission on August 12, 2025. 8.06% The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Y N See Item 2(a). Avoro Life Sciences Fund LLC has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5% of the Ordinary Shares. Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Exhibit 99.1: Joint Filing Agreement Avoro Capital Advisors LLC /s/ Scott Epstein 11/14/2025 Behzad Aghazadeh /s/ Behzad Aghazadeh 11/14/2025